Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
Journal of Cancer Research and Clinical Oncology|January 10, 2016
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemiaMohamed El Missiry, Shady Adnan Awad, Hanna L Rajala, et al.
The Journal of Clinical Investigation|May 1, 2025
Inborn errors of immunity underlie clonal T cell expansions in large granular lymphocyte leukemiaCarlos Bravo-Perez, Carmelo Gurnari, Jani Huuhtanen, et al.
Science Advances|October 30, 2024
Ex vivo modeling of precision immuno-oncology responses in lung cancerBassel Alsaed, Johannes Smolander, Hanna Laitinen, et al.
Leukemia|March 31, 2021
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemiaSofie Lundgren, Mikko A I Keränen, Matti Kankainen, et al.
Leukemia|November 3, 2023
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuationJani Huuhtanen, Shady Adnan-Awad, Jason Theodoropoulos, et al.
Cancer Immunology Research|June 9, 2021
Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human MelanomaJacopo Chiaro, Henna H E Kasanen, Thomas Whalley, et al.
European Journal of Haematology|August 2, 2014
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, et al.
Leukemia|April 15, 2025
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemiaAnnika Dechow, Sanna Timonen, Aleksandr Ianevski, et al.
Experimental Hematology|July 31, 2012
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemiaAnna Kreutzman, Taina Jaatinen, Dario Greco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent MannerAnna Kreutzman, Beatriz Colom-Fernández, Ana Marcos Jiménez, et al.
Pageof 18